Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/32708
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lipson K.E. | en |
dc.contributor.author | Rogers P.A.W. | en |
dc.contributor.author | Heryanto B. | en |
dc.date.accessioned | 2021-05-14T11:05:15Z | en |
dc.date.available | 2021-05-14T11:05:15Z | en |
dc.date.copyright | 2003 | en |
dc.date.created | 20030414 | en |
dc.date.issued | 2012-10-19 | en |
dc.identifier.citation | Reproduction. 125 (3) (pp 337-346), 2003. Date of Publication: 01 Mar 2003. | en |
dc.identifier.issn | 1470-1626 | en |
dc.identifier.uri | https://repository.monashhealth.org/monashhealthjspui/handle/1/32708 | en |
dc.description.abstract | It has been suggested that endometrial angiogenesis in response to the sex steroids oestrogen and progesterone is mediated at a local level via compounds such as vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF) and platelet-derived growth factor (PDGF), acting through their respective tyrosine kinase receptors. The aim of the present study was to use SUGEN tyrosine kinase receptor angiogenic inhibitor compounds SU5416, SU5402, SU11652 and SU11685, to determine whether VEGF, FGF or PDGF play a role in mediating endometrial endothelial cell proliferation after administration of oestrogen and progesterone. Endometrial endothelial cell proliferation was induced in adult ovariectomized mice by either oestrogen alone for 24 h (E1), or a regimen using oestrogen alone, then progesterone with low dose oestrogen, followed by progesterone with high-dose oestrogen (PE) over a total of 7 days. Each angiogenesis inhibitor compound was injected daily for 4 days (100 mg kg-1 day-1, s.c.) before endometrial tissue collection at either the E1 or PE stage. This study also evaluated the effect of VEGF antiserum (0.2 ml, i.p.) on endothelial cell proliferation at the E1 stage. All four angiogenic inhibitor compounds significantly reduced endothelial cell proliferation activity at the E1 and PE stages. The greatest reduction in the endothelial cell proliferative index was at the E1 stage in the group treated with the VEGF receptor inhibitor SU5416 (2.5 +/- 0.7% versus 27.9 +/- 1.1%, P < 0.001), with a reduction of similar magnitude in the group treated with anti-VEGF antibody. At the PE stage, all four inhibitors significantly reduced endothelial cell proliferation to a similar extent, indicating that VEGF, FGF and PDGF are all involved. These results demonstrate that endometrial angiogenesis after acute oestrogen treatment is primarily mediated by VEGF, but that under the influence of combined oestrogen and progesterone, FGF and PDGF are also probably involved. | en |
dc.language | en | en |
dc.language | English | en |
dc.publisher | BioScientifica Ltd. (Euro House, 22 Apex Court, Woodlands, Bradley Stoke, Bristol BS32 4JT, United Kingdom) | en |
dc.title | Effect of angiogenesis inhibitors on oestrogen-mediated endometrial endothelial cell proliferation in the ovariectomized mouse. | en |
dc.type | Review | en |
dc.type.studyortrial | Review article (e.g. literature review, narrative review) | - |
dc.identifier.doi | http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1530/rep.0.1250337 | en |
dc.publisher.place | United Kingdom | en |
dc.identifier.pubmedid | 12611597 [http://www.ncbi.nlm.nih.gov/pubmed/?term=12611597] | en |
dc.identifier.source | 36395581 | en |
dc.identifier.institution | (Heryanto, Rogers) Centre for Women's Health Research, Monash Univ. Dept. Obstet./Gynaecol., Monash Medical Centre, 246 Clayton Road, Clayton, Vic. 3168, Australia (Lipson) SUGEN Inc., 230 East Grand Avenue, South San Francisco, CA 94080, United States | en |
dc.description.address | P.A.W. Rogers, Centre for Women's Health Research, Monash Univ. Dept. Obstet./Gynaecol., Monash Medical Centre, 246 Clayton Road, Clayton, Vic. 3168, Australia. E-mail: peter.rogers@med.monash.edu.au | en |
dc.description.publicationstatus | Embase | en |
dc.rights.statement | Copyright 2012 Elsevier B.V., All rights reserved. | en |
dc.identifier.authoremail | Rogers P.A.W.; peter.rogers@med.monash.edu.au | en |
item.fulltext | No Fulltext | - |
item.cerifentitytype | Publications | - |
item.openairetype | Review | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.grantfulltext | none | - |
Appears in Collections: | Articles |
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.